Rotigotina (Portuguese Wikipedia)
Analysis of information sources in references of the Wikipedia article "Rotigotina" in Portuguese language version.
refsWebsite
Global rank
Portuguese rank
low place
low place
low place
low place
aderis.com
- Development & Commercialization of rotigotine by Aderis (Aderis Pharmaceuticals making a reference for the commercialization of rotigotine)
doi.org
dx.doi.org
- Chen JJ, Swope DM, Dashtipour K, Lyons KE (dezembro de 2009). «Transdermal rotigotine: a clinically innovative dopamine-receptor agonist for the management of Parkinson's disease». Pharmacotherapy. 29 (12): 1452–1467. PMID 19947805. doi:10.1592/phco.29.12.1452
- Davies S (setembro de 2009). «Rotigotine for restless legs syndrome». Drugs of Today. 45 (9): 663–668. PMID 19956807. doi:10.1358/dot.2009.45.9.1399952
- Bertaina-Anglade V, La Rochelle CD, Scheller DK (outubro de 2006). «Antidepressant properties of rotigotine in experimental models of depression». European Journal of Pharmacology. 548 (1–3): 106–114. PMID 16959244. doi:10.1016/j.ejphar.2006.07.022
- Horn AS, Tepper P, Van der Weide J, Watanabe M, Grigoriadis D, Seeman P (outubro de 1985). «Synthesis and radioreceptor binding activity of N-0437, a new, extremely potent and selective D2 dopamine receptor agonist». Pharmaceutisch Weekblad. Scientific Edition. 7 (5): 208–211. PMID 2933633. doi:10.1007/bf02307578
- Kulisevsky J, Pagonabarraga J (fevereiro de 2010). «Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trials». Drug Safety. 33 (2): 147–161. PMID 20082541. doi:10.2165/11319860-000000000-00000
- Parkinson Study Group (dezembro de 2003). «A controlled trial of rotigotine monotherapy in early Parkinson's disease». Archives of Neurology. 60 (12): 1721–1728. PMID 14676046. doi:10.1001/archneur.60.12.1721
- Wingo TS, Evatt M, Scott B, Freeman A, Stacy M (2009). «Impulse control disorders arising in 3 patients treated with rotigotine». Clinical Neuropharmacology. 32 (2): 59–62. PMID 18978496. doi:10.1097/WNF.0B013E3181684542
- Wood M, Dubois V, Scheller D, Gillard M (fevereiro de 2015). «Rotigotine is a potent agonist at dopamine D1 receptors as well as at dopamine D2 and D3 receptors». British Journal of Pharmacology. 172 (4): 1124–1135. PMC 4314200. PMID 25339241. doi:10.1111/bph.12988
fdanews.com
- «SCHWARZ PHARMA ACQUIRES REMAINING RIGHTS TO ROTIGOTINE FROM ADERIS | FDAnews». www.fdanews.com (em inglês). Consultado em 11 de agosto de 2022
nih.gov
ncbi.nlm.nih.gov
- Chen JJ, Swope DM, Dashtipour K, Lyons KE (dezembro de 2009). «Transdermal rotigotine: a clinically innovative dopamine-receptor agonist for the management of Parkinson's disease». Pharmacotherapy. 29 (12): 1452–1467. PMID 19947805. doi:10.1592/phco.29.12.1452
- Davies S (setembro de 2009). «Rotigotine for restless legs syndrome». Drugs of Today. 45 (9): 663–668. PMID 19956807. doi:10.1358/dot.2009.45.9.1399952
- Bertaina-Anglade V, La Rochelle CD, Scheller DK (outubro de 2006). «Antidepressant properties of rotigotine in experimental models of depression». European Journal of Pharmacology. 548 (1–3): 106–114. PMID 16959244. doi:10.1016/j.ejphar.2006.07.022
- Horn AS, Tepper P, Van der Weide J, Watanabe M, Grigoriadis D, Seeman P (outubro de 1985). «Synthesis and radioreceptor binding activity of N-0437, a new, extremely potent and selective D2 dopamine receptor agonist». Pharmaceutisch Weekblad. Scientific Edition. 7 (5): 208–211. PMID 2933633. doi:10.1007/bf02307578
- Kulisevsky J, Pagonabarraga J (fevereiro de 2010). «Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trials». Drug Safety. 33 (2): 147–161. PMID 20082541. doi:10.2165/11319860-000000000-00000
- Parkinson Study Group (dezembro de 2003). «A controlled trial of rotigotine monotherapy in early Parkinson's disease». Archives of Neurology. 60 (12): 1721–1728. PMID 14676046. doi:10.1001/archneur.60.12.1721
- Wingo TS, Evatt M, Scott B, Freeman A, Stacy M (2009). «Impulse control disorders arising in 3 patients treated with rotigotine». Clinical Neuropharmacology. 32 (2): 59–62. PMID 18978496. doi:10.1097/WNF.0B013E3181684542
- Wood M, Dubois V, Scheller D, Gillard M (fevereiro de 2015). «Rotigotine is a potent agonist at dopamine D1 receptors as well as at dopamine D2 and D3 receptors». British Journal of Pharmacology. 172 (4): 1124–1135. PMC 4314200. PMID 25339241. doi:10.1111/bph.12988